Rallybio Competitors and Similar CompaniesClear all
Rallybio's competitors and similar companies include Veloxis Pharmaceuticals and MABION.
 Rallybio Rallybio is a clinical-stage biotechnology company developing drugs with the main focus on antibodies, small molecules, and engineered proteins. |  Veloxis Pharmaceuticals Veloxis Pharmaceuticals is a biopharmaceutical company that identifies, develops, and commercializes products used in transplantation and adjacent therapies. |  MABION Mabion is a biotechnology company engaged in research and development of biotechnology and biosimilar drugs to treat cancer, autoimmune, and metabolic diseases. | |
Founding Date | Founding Date 2018 | Founding Date 2002 | Founding Date 2007 |
Type | Type Public | Type Subsidiary | Type Public |
Tags | |||
Locations | Locations New Haven, US HQ Farmington, US | Locations København, DK HQ Cary, US Cary, US | Locations Konstantynów Łódzki, PL HQ |
Employees | Employees 28 | Employees 54 | Employees 95 |
Valuation ($) | Valuation ($) 43.1 m | Valuation ($) N/A | Valuation ($) 21.7 m |
Financial | |||
Revenue (est.) | Revenue (est.) $858k (FY, 2025) | Revenue (est.) kr39.5m (FY, 2018) | Revenue (est.) zł15.8m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods kr7.9m (FY, 2018) | Cost of goods zł24.1m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit kr31.6m (FY, 2018) | Gross profit (zł7.2m) (FY, 2025) |
Net income | Net income ($9m) (FY, 2025) | Net income (kr5.3m) (FY, 2018) | Net income (zł62.6m) (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised $ 182m | Total funding raised $ 60m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Veloxis Pharmaceuticals
HQ
København, DK
Veloxis Pharmaceuticals is a biopharmaceutical company that identifies, develops, and commercializes products used in transplantation and adjacent therapies.
View companyMABION
HQ
Konstantynów Łódzki, PL
Employees
95
Mabion is a biotechnology company engaged in research and development of biotechnology and biosimilar drugs to treat cancer, autoimmune, and metabolic diseases.
View company